Minimal change disease
Conditions
Interventions
Experimental group:Initially half of the glucocorticoid (orally taken at the beginning 0.5 mg/kg/d and decreased within 12 weeks) combined with anti-CD20 monoclonal antibody (1000 mg, intravenous drop
Control group:Treatment with adequate glucocorticoids (oral treatment at the beginning of 1mg/kg/d, with a minimum of 24 weeks of reduced suspension).
Sponsors
Shanghai East Hospital (South Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-75 years (inclusive); 2. The clinical manifestation is nephrotic syndrome 3. Voluntarily sign the informed consent form; 4. Pathologically confirmed diagnosis of "minimal change nephropathy" through renal biopsy without immunosuppressive therapy;
Exclusion criteria
Exclusion criteria: 1. Allergy to glucocorticoids, anti-CD20 monoclonal antibodies, or inability to tolerate medications: 2. Secondary minimal change nephropathy (drugs, infections, tumors, etc.) or combined with other primary or secondary glomerular diseases; 3. Relapsed/refractory minimal change nephropathy; 4. Have used any kind of immunosuppressant within half a year; 5. Combined with diabetes mellitus; 6. Active hepatitis, cirrhosis, abnormal liver function such as alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) 2-3 times the upper limit of normal, total bilirubin more than 2 times the upper limit of normal; 7. Have severe active infection, HIV infection, active tuberculosis; 8. Combined malignant tumors 9. History of acute myocardial infarction within three months before entering the study, history of major surgical trauma within three months, etc.; 10. Pregnant and lactating females, or those who cannot guarantee effective contraception during childbearing age; 11. Those who suffer from mental disorders and take psychotropic drugs; 12. The doctor assessed that the patient was not easy to follow up or had poor compliance; 13. Patients who are unwilling to sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urine protein quantification;Renal function ;Serum albumin;Liver function; | — |
Countries
China
Contacts
Public ContactNa Liu
Shanghai East Hospital
Outcome results
None listed